

7 February 2023

Anti-VEGF treatments for eye conditions September to December 2022

1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept	3914
Bevacizumab	6
Brolucizumab	0
Dexamethasone	41
Faricimab	0
Ranibizumab – Lucentis	1388
Ranibizumab – Ongavia	0

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept	135
Bevacizumab	2
Brolucizumab	0
Dexamethasone	17
Faricimab	0
Ranibizumab – Lucentis	23
Ranibizumab – Ongavia	0